Voglio sapere a riguardo di…

Federal Register / Vol. 86, No. 51 / Thursday, March 18, 2021 / Proposed Rules based on whether applicable State law provides that the surplus lines insurer is eligible or not disapproved to place insurance in that State. Even if the surplus lines insurer is not considered to be engaged in the business of insurance under applicable State law, the surplus lines insurer would still be otherwise approved only for purposes of this provision of the Regulation if the insurer is eligible or not disapproved to place insurance in the State.
Private Flood Compliance 11. May a lender accept a private flood insurance policy that includes a compliance aid assurance clause, but also includes a disclaimer explaining that the insurer is not licensed in the State or jurisdiction in which the property is located, which suggests that the policy is issued by a surplus lines insurer?
Even if the policy includes a statement indicating that the insurer is not licensed in the State or jurisdiction in which the property is located, suggesting that the policy is issued by a surplus lines insurer, there are circumstances under which lenders may accept the policy. A lender may accept a policy issued by a surplus lines insurer recognized or not disapproved by the relevant State insurance regulator as protection for loan collateral that is a commercial property. Also, a lender may accept a policy issued by a surplus lines insurer as protection for loan collateral that is a noncommercial property as a policy issued by an insurance company that is otherwise approved to engage in the business of insurance by the insurance regulator of the State or jurisdiction in which the property to be insured is located. See Q&A Private Flood Compliance 10.
Blake J. Paulson, Acting Comptroller of the Currency.
Ann Misback, Secretary of the Board.

jbell on DSKJLSW7X2PROD with PROPOSALS

Federal Deposit Insurance Corporation.
Dated at Washington, DC, on or about January 12, 2021.
James P. Sheesley, Assistant Executive Secretary.
Dated at McLean, VA, this 1st day of March 2021.
Dale Aultman, Secretary, Farm Credit Administration Board.
Melane Conyers-Ausbrooks, Secretary of the Board, National Credit Union Administration.
FR Doc. 202105314 Filed 31721; 8:45 am BILLING CODE 481033P; 621001P; 671401P;
753501P; 670501P

VerDate Sep<11>2014

16:14 Mar 17, 2021

Jkt 253001

DEPARTMENT OF JUSTICE
Drug Enforcement Administration 21 CFR Part 1308
Docket No. DEA806

Schedules of Controlled Substances:
Placement of Four Specific FentanylRelated Substances in Schedule I
Drug Enforcement Administration, Department of Justice.
ACTION: Notice of proposed rulemaking.
AGENCY:

The Drug Enforcement Administration proposes placing ethyl 1-phenethylpiperidin-4ylphenylcarbamate fentanyl carbamate, N-2-fluorophenyl-N-1phenethylpiperidin-4-ylacrylamide ortho-fluoroacryl fentanyl, N-2fluorophenyl-N-1-phenethylpiperidin4-ylisobutyramide orthofluoroisobutyryl fentanyl, and N-4fluorophenyl-N-1-phenethylpiperidin4-ylfuran-2-carboxamide para-fluoro furanyl fentanyl, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, in schedule I of the Controlled Substances Act.
These four specific substances fall within the definition of fentanyl-related substances set forth in the February 6, 2018, temporary scheduling order.
Through the Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act, which became law on February 6, 2020, Congress extended the temporary control of fentanyl-related substances until May 6, 2021. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I
controlled substances on persons who handle manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess, or propose to handle fentanyl carbamate, ortho-fluoroacryl fentanyl, ortho-fluoro isobutyryl fentanyl, and para-fluoro furanyl fentanyl.
DATES: Comments must be submitted electronically or postmarked on or before April 19, 2021.
Requests for hearing and waivers of an opportunity for a hearing or to participate in a hearing must be received on or before April 19, 2021.
ADDRESSES: To ensure proper handling of comments, please reference Docket No. DEA806 on all electronic and written correspondence, including any attachments.
Electronic comments: Interested persons may file written comments on SUMMARY:

PO 00000

Frm 00013

Fmt 4702

Sfmt 4702

14707

this proposal in accordance with 21 CFR
1308.43g. The Drug Enforcement Administration DEA encourages that all comments be submitted electronically through the Federal eRulemaking Portal which provides the ability to type short comments directly into the comment field on the web page or to attach a file for lengthier comments. Please go to http
www.regulations.gov and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on Regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.
Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
Paper comments: Paper comments that duplicate the electronic submission are not necessary. Should you wish to mail a paper comment in lieu of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attn: DEA
Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
Hearing requests: Interested persons may file a request for hearing or waiver of hearing pursuant to 21 CFR 1308.44
and in accordance with 21 CFR 1316.45
and/or 1316.47, as applicable. All requests for hearing and waivers of participation must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing and waivers of participation should also be sent to: 1 Drug Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and 2 Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT:

Terrence L. Boos, Drug and Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia 22152; Telephone: 571 3623249.
SUPPLEMENTARY INFORMATION:

E:FRFM18MRP1.SGM

18MRP1